EuMentis is developing clinical-stage and preclinical therapeutics focused on neurodevelopmental and neuropsychiatric conditions, including autism spectrum disorder (ASD), Tourette syndrome (TS), and traumatic brain injury (TBI). Its lead programs are EM-113, described in the filing as an uncompetitive fast-off N-methyl-D-aspartate receptor (NMDAR) modulator being advanced for an ASD patient subset, and EM-221, a best-in-class oral PDE10A inhibitor designed to modulate dopaminergic circuits for TS. The company plans to initiate Phase 2 clinical trials for EM-113 in ASD and EM-221 in TS in the second half of the year. EuMentis also has a preclinical pipeline of next-generation fast-off NMDAR antagonists for TBI and other CNS indications and plans IND enabling work and Phase 1 studies for those candidates. The company cited a $3 million grant award from the U.S. Department of Defense to support preclinical TBI studies. EuMentis was founded in 2019 and is privately held.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2023